(380v) ZnO Nanoparticles Incorporated MIL-100 for Doxorubicin Delivery
AIChE Annual Meeting
2019
2019 AIChE Annual Meeting
Particle Technology Forum
Poster Session: Particle Technology Forum
Tuesday, November 12, 2019 - 3:30pm to 5:00pm
Abhik Bhattacharjee Windows User 2 1 2019-04-12T17:08:00Z 2019-04-12T17:08:00Z 1 250 1425 11 3 1672 16.00
Clean Clean false false false false EN-US X-NONE X-NONE
text-align:center">
MIL-100 and its composites were synthesised and evaluated
as potential carriers for doxorubicin hydrochloride. An iron based
MOF, MIL-100 was synthesised at
150 °C using Trimesic acid (BTC) and iron powder. Zinc oxide (ZnO) nanopartcles,
that are bio-friendly and used in pharmaceutical
applications were chosen to prepare MOF composites. At first, ZnO was
prepared by wet chemical method using of Zn 2+ salt under reflux conditions. A series of
composite named ZnO@MIL-100 (Z@M_F) were prepared by adding these ZnO
nanoparticles (in varying mass %) to
the precursor solution of MIL-100. The composite
were characterised by X-ray diffraction, Nitrogen adsorption-desorption
isotherms and Transmission electron microscopy (TEM). justify;line-height:normal;background:white;vertical-align:baseline"> justify;line-height:normal;background:white;vertical-align:baseline">Doxorubicin hydrochloride (DOX), an anticancer drug used in treatment of
diseases such as leukaemia, lymphoma, and carcinoma was chosen as a model drug. Initially, DOX was loaded
on different MOF composites. The DOX loading was
estimated through analysis of the solution phase by UV-Vis
spectrophotometer. The drug release experiments from these composites
loaded with DOX, were carried out in simulated
phosphate-buffered saline (PBS) solution of pH 7.4 at 37 °C. The highest DOX
loading capacity was found ~21% for Z2@M_F.
The release experiments indicate sustained and release of DOX after
incorporation of ZnO nanoparticles in the MOF structure. text-align:center;line-height:150%"> mso-bidi-font-size:11.0pt;line-height:150%;font-family:" times new roman> text-align:center;line-height:150%"> 11.0pt;line-height:150%;font-family:" times new roman en-in>Table : DOX loading details
justify;line-height:150%">
11.0pt;line-height:150%;font-family:" times new roman en-in>
line-height:150%;font-family:" times new roman> justify;line-height:150%"> 11.0pt;line-height:150%;font-family:" times new roman> justify;line-height:150%"> 11.0pt;line-height:150%;font-family:" times new roman>
justify;line-height:normal;background:white;vertical-align:baseline">In the present study, an iron based metal organic framework (MOF)
MIL-100 and its composites were synthesised and evaluated
as potential carriers for doxorubicin hydrochloride. An iron based
MOF, MIL-100 was synthesised at
150 °C using Trimesic acid (BTC) and iron powder. Zinc oxide (ZnO) nanopartcles,
that are bio-friendly and used in pharmaceutical
applications were chosen to prepare MOF composites. At first, ZnO was
prepared by wet chemical method using of Zn 2+ salt under reflux conditions. A series of
composite named ZnO@MIL-100 (Z@M_F) were prepared by adding these ZnO
nanoparticles (in varying mass %) to
the precursor solution of MIL-100. The composite
were characterised by X-ray diffraction, Nitrogen adsorption-desorption
isotherms and Transmission electron microscopy (TEM). justify;line-height:normal;background:white;vertical-align:baseline"> justify;line-height:normal;background:white;vertical-align:baseline">Doxorubicin hydrochloride (DOX), an anticancer drug used in treatment of
diseases such as leukaemia, lymphoma, and carcinoma was chosen as a model drug. Initially, DOX was loaded
on different MOF composites. The DOX loading was
estimated through analysis of the solution phase by UV-Vis
spectrophotometer. The drug release experiments from these composites
loaded with DOX, were carried out in simulated
phosphate-buffered saline (PBS) solution of pH 7.4 at 37 °C. The highest DOX
loading capacity was found ~21% for Z2@M_F.
The release experiments indicate sustained and release of DOX after
incorporation of ZnO nanoparticles in the MOF structure. text-align:center;line-height:150%"> mso-bidi-font-size:11.0pt;line-height:150%;font-family:" times new roman> text-align:center;line-height:150%"> 11.0pt;line-height:150%;font-family:" times new roman en-in>Table : DOX loading details
|
Sr. No. |
Sample |
DOX loading (%) |
|
01 |
MIL-100 |
10.8 |
|
02 |
Z1@M_F |
13.3 |
|
03 |
Z2@M_F |
21.2 |
|
04 |
Z3@M_F |
20.4 |
line-height:150%;font-family:" times new roman> justify;line-height:150%"> 11.0pt;line-height:150%;font-family:" times new roman> justify;line-height:150%"> 11.0pt;line-height:150%;font-family:" times new roman>